Wayne Kuznar
Dupilumab tames AD in difficult-to-treat patients
Dupilumab given concomitantly with topical corticosteroids significantly improved signs and symptoms of atopic dermatitis (AD) in adults refractory to or intolerant of cyclosporine A, a study shows.
Recapture remission in chronic idiopathic urticaria
In CIU, omalizumab retreatment recaptures remission in relapsers following drug withdrawal.
Water ablation’s safety, efficiency in BPH assessed
An image-guided technique for treating LUTS associated with BPH is reproducible and promising, researchers say.
Bipolar vaporization: Do benefits outweigh risks?
A large, randomized trial provides a head-to-head comparison of late complications involving the two approaches to BPH.
Significant OS improvement seen with mCRPC Tx vs. placebo
Charles J. Ryan, MD, recently presented the final analysis of the COU-AA-302 study of abiraterone acetate (ZYTIGA) versus placebo.
RARP vs. open: Outcomes from 650,000 patients
The review “represents the best available evidence for the morbidity and cost profile” of robot-assisted versus open radical prostatectomy, says one of the study’s authors.
Bariatric surgery for type 2 diabetes: Reaching too far?
Although bariatric surgery is becoming an increasingly accepted option to reverse type 2 diabetes, lifestyle interventions, including smoking cessation, improved nutrition, and increased physical activity, coupled with appropriate pharmacotherapy, remain the mainstays for the management of type 2 diabetes.
Alpha-lipoic acid protects beta-cell function and improves insulin sensitivity
A small clinical study shows improvements in insulin secretion and insulin sensitivity and prevention of oxidative stress with the use of alpha-lipoic acid in obese persons with impaired glucose tolerance (IGT), according to Chinese researchers.
Attacking kidney's sodium glucose cotransporter may have advantages in type 2 diabetes
Inhibitors of sodium glucose cotransporter (SGLT)-2 offer the promise of reducing fasting glucose and hemoglobin A1c (HbA1c) levels, independent of acting on insulin, while reducing weight, says John P. Wilding, DM. Several SGLT-2 inhibitors are in development, and one, dapagliflozin, is in phase 3 clinical studies.
Insulin resistance, beta-cell dysfunction start several years before diabetes diagnosis
Metabolic changes occur well before an actual diagnosis of type 2 diabetes, providing opportunities for screening and prevention, say British researchers. Results of the WHITEHALL II study suggest both insulin resistance and beta-cell dysfunction are likely present years before a diabetes diagnosis.


View Results